黛力新联合氟桂利嗪防治偏头痛的Meta分析

目的系统评价黛力新(氟哌噻吨美利曲辛)联合氟桂利嗪防治偏头痛的有效性和安全性。方法计算机检索Embase、Pubmed、Cochrane图书馆临床对照试验资料库、CNKI、维普及万方数据库,纳入黛力新联合氟桂利嗪防治偏头痛的随机对照试验文献(randomized controlled trials,RCT),按Cochrane系统评价的方法评价纳入研究质量,并使用Rev Man 5.1软件对纳入研究进行Meta分析。结果最终纳入符合条件的文献10篇,包括932例患者。Meta分析结果显示,黛力新联合氟桂利嗪组与氟桂利嗪组比较差异有统计学意义[OR=4.23,95%CI(2.90,6.17),P0.00001]。联合用药的不良反应与单独使用氟桂利嗪无明显差异[OR=1.14,95%CI(0.58,2.26),P=0.70]。结论现有限研究表明,黛力新联合氟桂利嗪防治偏头痛效果优于与单纯使用氟桂利嗪,且安全性良好。但本系统评价纳入文献数量有限,质量较低,尚需开展更多设计合理、执行严格的多中心大样本的随机对照试验验证其疗效及安全性。

Flupentixol and melitracen combined with flunarizine for preventing and treating migraine: a meta-analysis

Objective To systematically evaluate the efficacy and safety of flupentixol and melitracen combined with flunarizine for preventing and treating migraine.Methods Controlled clinical trials from Embase, PubMed, and Cochrane Library, CNKI, VIP, and Wanfang Data were searched, and randomized controlled trials (RCTs) of flupentixol and melitracen combined with flunarizine for preventing and treating migraine were included. The quality of the included studies was assessed by Cochrane systematic reviews, and a meta-analysis was carried out on the included studies with RevMan 5.1 software. Results Ten studies were included, involving 932 patients. Meta-analysis showed that there was a significant difference between the group using flupentixol and melitracen combined with flunarizine and the group using flunarizine alone for migraine [OR=4.23, 95%CI (2.90, 6.17), P<0.00001]. The adverse events of the two groups showed no significant differences [OR=1.14, 95%CI (0.58, 2.26), P=0.70]. Conclusions Limited studies show that flupentixol and melitracen combined with flunarizine has better efficacy compared with using flunarizine alone, and the safety is satisfactory as well. However, the included studies is limited in quantity and poor in quality, and therefore multi-centered and large-scale RCTs with rational design and strict execution are needed to validate its efficacy and safety.